Halloween has come and gone in the US, and Americans are now gearing up for Thanksgiving and Christmas. But before the holiday season could get underway, the country went through a major political event with far-reaching implications: the midterm elections.As…
REGULATORY
MHLW Study Group on Counterfeit Drugs to Discuss Issues such as GDP Later This Fiscal Year
The Ministry of Health, Labor and Welfare’s (MHLW) study group on counterfeit drugs completed its discussions in the first half of the current fiscal year by approving a draft interim report on June 8. In later this fiscal year, it…
To read the full story
Related Article
- Counterfeit Drug Panel OKs Final Report, MHLW to Issue GDP Guidelines in FY2018
December 27, 2017
- MHLW Counterfeit Drug Panel Agrees on “Voluntary” Introduction of GDP in Japan
November 14, 2017
- Japan Introduction of GDP Likely to Begin with Guideline that Calls on Companies to Make “Good Faith Effort”: MHLW Study Group
October 23, 2017
- MHLW Study Group Compile Draft Interim Report on Preventing Distribution of Counterfeit Drugs
June 12, 2017
REGULATORY
- MOF Panel Pushes for Full Drug Price Revision in FY2027: Budget Proposal
November 20, 2026
- Mumps Shots Gain Strong Backing as Japan Weighs FY2027 NIP Priorities
November 20, 2026
- Lilly’s Oral GLP-1 Obesity Drug Heads to Dec. 2 Panel Review, Eyes Japan First
November 19, 2026
- Pharma Prods LDP to Rethink CEA Expansion, Project Team to Compile Proposal
November 19, 2026
- First Pralia Biosimilars Inching Closer to Japan Approval, 5 Products Lined Up
November 19, 2026





